Evidence map›Paper›PMID 29616834›Full record

ArticleLeukemia & lymphoma2018

Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy.

Chelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, Therese Y Andraos, Michalis Aristophanous, Mary Pham, Donald Hancock, Ethan B Ludmir, Jillian R Gunther, Michelle A Fanale and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chelsea C Pinnixa Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.ORCID 0000-0003-3982-3664
Andrew Wirthb Department of Radiation Oncology , Peter MacCallum Cancer Institute , Melbourne , Australia.
Sarah A Milgroma Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Therese Y Andraosa Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Michalis Aristophanousa Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Mary Phama Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Donald Hancocka Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Ethan B Ludmira Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Jillian R Gunthera Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Michelle A Fanalec Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Yasuhiro Okic Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Loretta Nastoupilc Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Hubert H Chuangd Department of Nuclear Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
N George Mikhaeele Department of Clinical Oncology , Guy's and St. Thomas' Hospital , London , UK.
Bouthaina S Dabajaa Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Cardiophrenic lymph nodes (CPLNs) are occasionally involved in Hodgkin lymphoma (HL). We characterized the incidence of CPLN involvement among 169 HL patients and evaluated outcomes after treatment with omission of the CPLN region from the involved-site radiation therapy (ISRT) field. Three types of RT fields were used: standard (S)-ISRT, reduced-dose (RD)-ISRT (lower dose to CPLNs, standard to other sites), or modified (M)-ISRT (omission of CPLNs). CPLNs were involved at diagnosis in 29 patients (17%). Of the 20 patients who received RT after complete response to chemotherapy, 4(20%) received S-ISRT, 8(40%) RD-ISRT, and 8(40%) M-ISRT. The four-year progression-free survival was 94.7%. One relapse occurred at a non-CPLN site after RD-ISRT. The mean heart dose and volume of the heart that received 25 Gy was higher for S-ISRT patients compared to M-ISRT (

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDoxorubicinEtoposideFemaleFollow-Up StudiesHeartHodgkin DiseaseHumansMaleMiddle AgedNeoplasm Recurrence, LocalBleomycinDacarbazineDoxorubicinEtoposideVinblastinecardiophrenic lymph nodesHodgkin lymphomaradiation therapy

Identifiers

PMID29616834
PMCPMC6363900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.